Insulet Valuation Multiples

Insulet Overview

About Insulet

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.

Founded

2000

HQ

Employees

5.4K

Website

insulet.com

Sectors

Medical DevicesBioTechDeepTechHealthTech

Financials (LTM)

Revenue: $3B

EBITDA: $671M

EV

$17B

Valuation Multiples

Multiples.vc

Start free trial

Insulet Financials

Insulet reported last 12-month revenue of $3B and EBITDA of $671M.

In the same LTM period, Insulet generated $2B in gross profit, $671M in EBITDA, and $374M in net income.

Insulet P&L

In the most recent fiscal year, Insulet reported revenue of $3B and EBITDA of $640M.

Insulet expects next 12-month revenue of XXX and NTM EBITDA of XXX

Insulet Stock Performance

Insulet has current market cap of $17B, and enterprise value of $17B.

Insulet's stock price is $242.89.

Insulet Valuation Multiples

Insulet trades at 6.1x EV/Revenue multiple, and 25.8x EV/EBITDA.

Insulet Financial Valuation Multiples

As of March 19, 2026, Insulet has market cap of $17B and EV of $17B.

Equity research analysts estimate Insulet's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Insulet has a P/E ratio of 45.7x.

Insulet Margins & Growth Rates

Insulet's revenue in the last 12 month grew by 22%.

Insulet's revenue per employee in the last FY averaged $0.5M.

Insulet's rule of 40 is 45% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Insulet's rule of X is 78% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Insulet Public Comps

See public comps and valuation multiples for other Medical Devices comps.

Insulet M&A Activity

Insulet acquired XXX companies to date.

Last acquisition by Insulet was on XXXXXXXX, XXXXX. Insulet acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Insulet Investment Activity

Insulet invested in XXX companies to date.

Insulet made its latest investment on XXXXXXXX, XXXXX. Insulet invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).